Stockscreener 앱 받기
0.91
10.78%
-0.11
시간 외 거래:
.92
0.01
+1.10%
Estrella Immunopharma Inc 주식(ESLA)의 최신 뉴스
Tranche Update on Estrella Immunopharma, Inc.'s Equity Buyback Plan announced on January 30, 2024. - marketscreener.com
Estrella Immunopharma, Inc. (ESLA) 8-K Filing: Shareholder Vote Results & Company Details – June 2026 - Minichart
Estrella Immunopharma Shareholders Ratify 2026 Auditor Appointment - TipRanks
Estrella Immunopharma (ESLA) investors back 2026 auditor at virtual annual meeting - Stock Titan
Enterprise value to EBITDA forward of Estrella Immunopharma, Inc. – BOATS:ESLAW - TradingView
Price to earnings forward of Estrella Immunopharma, Inc. – BOATS:ESLAW - TradingView
Estrella Immunopharma Warrants (ESLAW) Edge Lower Amid Thin TradingCall Flow Alert - dars.gov.et
Estrella Immunopharma, Inc.(NasdaqCM:ESLA) added to Russell Microcap Value Benchmark Index - marketscreener.com
Estrella Immunopharma, Inc.(NasdaqCM: ESLA) added to Russell 3000E Value Benchmark - marketscreener.com
Estrella Immunopharma, Inc. Actuals & Estimates (NASDAQ:ESLA) - TradingView
Estrella Immunopharma Inc (ESLA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Estrella Immunopharma Inc (ESLA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Estrella Immunopharma Inc (ESLA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Estrella Immunopharma Inc (ESLA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Estrella Immunopharma Inc (ESLA) Institutional Confidence - TradingKey
Estrella Immunopharma Inc (ESLA) Valuation: PE, PB & Fair Value Analysis - TradingKey
Estrella Immunopharma Inc. (ESLA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Estrella Immunopharma Inc (ESLAW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Estrella Immunopharma Inc (ESLAW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Estrella Immunopharma Inc - TradingKey
Estrella Immunopharma Inc (ESLAW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Estrella Immunopharma Inc (ESLAW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Estrella Immunopharma Inc (ESLAW) Institutional Confidence - TradingKey
Estrella Immunopharma Inc (ESLA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Estrella Immunopharma Inc (ESLAW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Estrella Immunopharma Inc (ESLA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Estrella Immunopharma Inc (ESLAW) Valuation: PE, PB & Fair Value Analysis - TradingKey
Estrella Immunopharma Inc (ESLA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Estrella Immunopharma Inc. (ESLA) Q1 2026 Earnings: Miss on EPS as Pre-Revenue Biotech Navigates Clinical DevelopmentEarnings Surprise Stocks - newsline.com
Estrella Immunopharma (ESLA) Edges Higher Amid Broader Biotech SentimentWyckoff Accumulation - newsline.com
ESLAW Warrants Slide 13% as Support at $0.10 Faces Critical TestStop Hunt - newsline.com
ESLA Q1 2026 Earnings: Wider Loss Than Expected Amid Pre-Revenue Development StageEPS Revision Trend - newsline.com
ESLA Q1 2026 Earnings: EPS Misses Estimates by Wide Margin as Stock Rises 10.6%Earnings Sentiment Score - newsline.com
ESLA Q1 2026 Earnings: Wider-than-Expected Loss as Pre-revenue Biotech Continues DevelopmentEarnings Revision Report - The Legal Advocate
Estrella Immunopharma Warrants (ESLAW) Hold Steady at $0.13 – Key Levels in FocusSuperTrend - dars.gov.et
Estrella Immunopharma (ESLA) Edges Lower Near Support as Biotech Sector Faces HeadwindsMutual Fund Flow - The Legal Advocate
ESLAW Surges 22.52%: Estrella Immunopharma Warrant Breaks Above SupportVolatility Surface - The Legal Advocate
Estrella Immunopharma Inc. (ESLA) Shows Modest Uptick Amid Sector StabilityLinear Regression - The Legal Advocate
Estrella Immunopharma (ESLA) sets virtual 2026 meeting to ratify auditor - Stock Titan
Estrella Immunopharma Warrant (ESLAW) Surges 18.85% to $0.10, Faces Key Resistance at $0.11Volume Breadth - The Legal Advocate
Estrella Immunopharma (ESLA) Q1 2026 Earnings: Wider-Than-Expected Loss Triggers Modest Stock GainLow Growth Earnings - Newser
ESLA Q1 2026 Earnings: Wider-Than-Expected Loss and No Revenue Highlight Development-Stage Challenges - newsline.com
Estrella Immunopharma (ESLA) Q1 2026 Earnings Slump: EPS Falls Short of $-0.18 TargetHigh Interest Stocks - Newser
Estrella Immunopharma, Inc. 2026 Q1 Financial Report: Key Financials, Related Party Transactions, and R&D Update - Minichart
Estrella Immunopharma (ESLA) Q1 2026 Earnings Miss by Significant: Key TakeawaysEPS Growth Rate - Newser
Estrella Immunopharma, Inc. 1Q 2026: Net income $(2.29M), EPS $(0.05) — 10-Q Summary - TradingView
Estrella Immunopharma (ESLA) Stock Analysis: Falls -6.22%, Watching $1.07 2026-05-15Popular Market Picks - newser.com
[SCHEDULE 13G] Estrella Immunopharma, Inc. Passive Investment Disclosure (>5%) - Stock Titan
TradingKey - TradingKey
The quiet positioning of Estrella (ESLAW) nobody discusses (Moonwalks) 2026-05-08Bullish Pattern - newser.com
Estrella Immunopharma (ESLA) Q1 loss deepens, EPS miss of 90.6 percent rattles investor confidence.Special Dividend Alert - The Legal Advocate
Estrella Immunopharma (ESLA) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Estrella Immunopharma to Participate in the D. Boral Capital Global Conference - BioSpace
10-K/A: Annual report (Amendment) - Moomoo
Is Estrella (ESLAW) stock a safe investment |Revenue Warning Signal - newsline.com
1.17%
2.48%
자본화:
|
볼륨(24시간):